Waqar, Saiama N.

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Pietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Research StudiesPARP inhibition in cancer therapy

Cited by 399

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 206

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 146

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., et al. (2021) · npj Precision Oncology

Neuroendocrine Tumor Research AdvancesMonoclonal and Polyclonal Antibodies Research

Cited by 80